Two Spanish companies develop a PCR test that identifies one of the origins of migraine

"Various studies have shown a significant difference in plasma histamine concentration and the incidence of DAO deficiency in the population suffering from migraine, the prevalence of which is 87%. This high prevalence of DAO deficiency in patients with migraine positions the activity of this enzyme as a possible biological marker, which opens a new paradigm both in the objective diagnosis of the migraine's origin and in its subsequent treatment using a dietary approach. And also to our PCR project," explains Ana Castillo, head of medical nutrition at DR Healthcare.

MADRID, 16/09/2020 (informazione.news - comunicati stampa - scienza e tecnologia)

explains Ana Castillo , head of medical nutrition at DR Healthcare.

This cooperation between Genyca and DR Healthcare began in 2019 in Spain through pharmacy offices and is now expanding its commercialization internationally through large networks of diagnostic laboratories.

 explains the scientific director of Genyca, Teresa Perucho .

Migraine is the most common neurological disorder, , according to the  &  . This disease is more common among women; 17% of women while the percentage among men remains at 8%. Migraine presents a significant incidence in young population and, as it is a pain of severe intensity, it has a great impact on work, social and family activities in this group of patients.

. Published studies indicate that SAR COV -2 infection causes a release of cytokines from mast cells, accompanied by a release of , which could justify the triggering of migraine in people diagnosed with Covid-19 as well as the recommendation to control intake of exogenous histamine.